EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Clinical effectiveness of routine first‐trimester combined screening for pre‐eclampsia in Spain with the addition of placental growth factor

Pablo Garcia-Manau iD, Erika Bonacina iD, Berta Serrano iD, Sara Caamiña, Marta Ricart, Eva Lopez-Quesada, Àngels Vives, Monica Lopez, Elena Pintado, Anna Maroto, Sara Catalan, Marta Dalmau and 7 more

Acta Obstetricia et Gynecologica Scandinavica · 2023

DOI: 10.1111/aogs.14687 ↗

At a glance

Multizentrische Studie in Acta Obstetricia et Gynecologica Scandinavica, 2023. Written by Pablo Garcia-Manau and 18 co-authors. Institution: Universitat Autònoma de Barcelona, Barcelona, Spain. Major MEDLINE topics: Pre-Eclampsia, Premature Birth. Cited 9 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Pre‐eclampsia affects 2%–8% of pregnancies and is one of the leading causes of maternal and perinatal morbidity and mortality. First‐trimester screening using an algorithm that combines maternal characteristics, mean arterial blood pressure, uterine artery pulsatility index and biomarkers (pregnancy‐associated plasma protein‐A and placental growth factor) is the method that achieves a greater diagnostic accuracy. It has been shown that daily salicylic acid administration before 16 weeks in women at a high risk for pre‐eclampsia can reduce the incidence of preterm pre‐eclampsia. However, no previous studies have evaluated the impact of routine first‐trimester combined screening for pre‐eclampsia with placental growth factor after being implemented in the clinical practice. Material and methods This was a multicenter cohort study conducted in eight different maternities across Spain. Participants in the reference group were prospectively recruited between October 2015 and September 2017. Participants in the study group were retrospectively recruited between March 2019 and May 2021. Pre‐eclampsia risk was calculated between 11 +0 and 13 +6 weeks using the Gaussian algorithm combining maternal characteristics, mean arterial pressure, uterine arteries pulsatility index, pregnancy‐associated plasma protein‐A and placental growth factor. Patients with a risk greater than 1/170 were prescribed daily salicylic acid 150 mg until 36 weeks. Patients in the reference group did not receive salicylic acid during gestation.

Results

A significant reduction was observed in preterm pre‐eclampsia (OR 0.47; 95% CI: 0.30–0.73), early‐onset (

Subjects

MeSH terms (MEDLINE)

Pre-EclampsiaPremature BirthPregnancyFemaleHumansInfant, NewbornPregnancy Trimester, FirstPlacenta Growth FactorPregnancy-Associated Plasma Protein-ACohort StudiesSpainRetrospective StudiesRisk AssessmentSalicylic AcidTreatment OutcomeBiomarkersUterine ArteryPulsatile Flow

Author keywords

PlGFaspirinplacental growth factorpre-eclampsiasalicylic acidscreening

Substances

Placenta Growth FactorPregnancy-Associated Plasma Protein-ASalicylic AcidBiomarkers

Authors and institutions

  • Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Department of Obstetrics, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
  • Department of Obstetrics, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Department of Obstetrics, Hospital Universitari Mútua Terrassa, Terrassa, Spain.
  • Department of Obstetrics, Consorci Sanitari de Terrassa, Terrassa, Spain.

ORCID profiles: Pablo Garcia-Manau, Erika Bonacina, Berta Serrano, Ester Del Barco, Manel Mendoza

Cite

APA

Garcia-Manau, P., Bonacina, E., Serrano, B., Caamiña, S., Ricart, M., Lopez-Quesada, E., Vives, À., Lopez, M., Pintado, E., Maroto, A., Catalan, S., Dalmau, M., Del Barco, E., Hernandez, A., Miserachs, M., San Jose, M., Armengol-Alsina, M., Carreras, E., & Mendoza, M. (2023). Clinical effectiveness of routine first‐trimester combined screening for pre‐eclampsia in Spain with the addition of placental growth factor. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14687

Vancouver

Garcia-Manau P, Bonacina E, Serrano B, Caamiña S, Ricart M, Lopez-Quesada E, et al. Clinical effectiveness of routine first‐trimester combined screening for pre‐eclampsia in Spain with the addition of placental growth factor. Acta Obstetricia et Gynecologica Scandinavica. 2023. doi:10.1111/aogs.14687

BibTeX
@article{GarciaManau2023,
  author = {Garcia-Manau, Pablo and Bonacina, Erika and Serrano, Berta and Caamiña, Sara and Ricart, Marta and Lopez-Quesada, Eva and Vives, Àngels and Lopez, Monica and Pintado, Elena and Maroto, Anna and Catalan, Sara and Dalmau, Marta and Del Barco, Ester and Hernandez, Alina and Miserachs, Marta and San Jose, Marta and Armengol-Alsina, Mireia and Carreras, Elena and Mendoza, Manel},
  title = {Clinical effectiveness of routine first‐trimester combined screening for pre‐eclampsia in Spain with the addition of placental growth factor},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2023},
  doi = {10.1111/aogs.14687}
}
Start for free →